Literature DB >> 17671295

Exacerbation of schizophrenia by varenicline.

Robert Freedman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671295     DOI: 10.1176/appi.ajp.2007.07020326

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  49 in total

1.  Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats.

Authors:  Amir H Rezvani; Susan Slade; Cori Wells; Ann Petro; Lawrence Lumeng; Ting-Kai Li; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Jed E Rose; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2010-06-10       Impact factor: 4.530

Review 2.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

3.  Varenicline treatment for smokers with schizophrenia: a case series.

Authors:  A Eden Evins; Donald C Goff
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

4.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

5.  Smoking cessation: the psychiatrist's role.

Authors:  Nicholas J Delva
Journal:  J Psychiatry Neurosci       Date:  2008-09       Impact factor: 6.186

6.  Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.

Authors:  Serena Tonstad; Simon Davies; Martina Flammer; Cristina Russ; John Hughes
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

7.  Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.

Authors:  Mark G LeSage; David Shelley; Jason T Ross; F Ivy Carroll; William A Corrigall
Journal:  Pharmacol Biochem Behav       Date:  2008-09-09       Impact factor: 3.533

Review 8.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 9.  Varenicline for tobacco dependence.

Authors:  J Taylor Hays; Jon O Ebbert
Journal:  N Engl J Med       Date:  2008-11-06       Impact factor: 91.245

10.  An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.

Authors:  P Bader; P McDonald; P Selby
Journal:  Tob Control       Date:  2008-10-09       Impact factor: 7.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.